Action of comprehensive prevention of caries and non-caries damages on blood biochemical indicators in patients with estrogen imbalance

Abstract

Purpose of the study. To study the effect of means of complex prevention of caries and non-carious damages on the biochemical parameters of blood in patients with estrogen imbalance.
Materials and methods. For the study of biochemical parameters, 3 groups of patients were selected: The examination was carried out three times: the first examination—at the beginning of treatment; the second examination—3 months after the start of treatment; the third examination—6 months after the start of treatment. In the observation group, no additional treatment was carried out, only professional oral hygiene at the beginning of treatment and observation at the dentist. In the main group 1, a combination of calcium phosphate preparations with vitamin D3 was used (АТС А12А Х., Registration No. UA/10610/01/01 dated 9.4.2020). In the main group 2, a combination of calcium phosphate preparations with vitamin D3 (АТС А12А Х, No. UA/10610/01/01 dated 9.4.2020), alendronic acid preparation (АТХ М05В А04, Registration No. UA/7210/01/02 of September 20, 2017. Order No. 1116 of September 20, 2017). These drugs were prescribed in courses of 1 month with 1 month intervals between courses. Only 3 courses. To confirm the imbalance of estrogen, all patients were tested for the level of estrogen (estradiol) in the body. All patients were in the period of menopause, that is, they did not have cyclical fluctuations in hormone levels. For an indirect study of the degree of osteoporosis (the ratio of destruction and formation of bone tissue), we determined the level of acid phosphatase and alkaline phosphatase in blood serum. To study the state of calcium-phosphorus metabolism, studies of osteocalcin and neoganic phosphorus in the blood were carried out. Research results. In the main group 2, after 6 months of observation, the level of acid phosphatase was 2.41±0.19, which is 64.71 % (p6 < 0.05) less than the initial result. At the same time, the indicators in the main group 2 as of 6 months were less than the indicators in the main group 1 by 2.05 times (p7 < 0.05). In the main group 2 after 6 months, the level of alkaline phosphatase was 134.36±11.37, which is 113.44 % (p6 < 0.05) more than the initial result. At the same time, the indicators in the main group 2 as of 6 months were higher than the indicators in the main group 1 by 1.76 times (p7 < 0.05). In the main group 2 after 6 months, the level of osteocalcin was 15.73±3.12, which is 71.82 % (p6 < 0.05) less than the initial result. At the same time, the indicators in the main group 2 as of 6 months were less than the indicators of the main group 1 by 2.55 times (p7 < 0.05). In the main group 2, after 6 months of observation, the level of inorganic phosphorus was 1.62±0.18, which is 145.45 % (p6 < 0.05) more than the initial result. At the same time, the indicators in the main group 2 as of 6 months were higher than the indicators in the main group 1 by 1.76 times (p7 < 0.05).
Conclusions. The use of calcium phosphate preparations with vitamin D3 and aminobisphosphonates (alentronic acids) for 6 months significantly reduces the activity of acid phosphatase by 64.71 % (p6 < 0.05). The use of calcium phosphate preparations with vitamin D3 and aminobisphosphonates (alendronic acid) for 6 months significantly increase the activity of alkaline phosphatase by 113.44 % (p6 < 0.05). The use of calcium phosphate preparations with vitamin D3 and aminobisphosphonates lasting 6 months statistically significantly reduces the level of osteocalcin by 71.82 % (p6 <0.05). The use of calcium phosphate preparations with vitamin D3 and aminobisphosphonates (alendronic acid) lasting 6 months increase phosphorus absorption by 145.45 % (p6 < 0.05).